Cargando…

Assessment of the efficacy and toxicity of (131)I-metaiodobenzylguanidine therapy for metastatic neuroendocrine tumours

(131)I-metaiodobenzylguanidine ((131)I-MIBG) is a licensed palliative treatment for patients with metastatic neuroendocrine tumours. We have retrospectively assessed the consequences of (131)I-MIBG therapy in 48 patients (30 gastroenteropancreatic, 6 pulmonary, 12 unknown primary site) with metastat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nwosu, A C, Jones, L, Vora, J, Poston, G J, Vinjamuri, S, Pritchard, D M
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2008
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2275478/ https://www.ncbi.nlm.nih.gov/pubmed/18283308 http://dx.doi.org/10.1038/sj.bjc.6604273

Ejemplares similares

Peptide receptor radionuclide therapy with (90)Y-DOTATATE/(90)Y-DOTATOC in patients with progressive metastatic neuroendocrine tumours: assessment of response, survival and toxicity
por: Vinjamuri, S, et al.
Publicado: (2013)

Toxicity of upfront (131)I-metaiodobenzylguanidine ((131)I-MIBG) therapy in newly diagnosed neuroblastoma patients: a retrospective analysis
por: Bleeker, Gitta, et al.
Publicado: (2013)

Complete remission of metastatic pheochromocytoma in (123)I-metaiodobenzylguanidine scintigraphy after a single session of (131)I-metaiodobenzylguanidine therapy: a case report
por: Sugino, Teruaki, et al.
Publicado: (2017)

The role of (131)I-metaiodobenzylguanidine (MIBG) therapy in unresectable and compromising localised neuroblastoma
por: Schoot, Reineke A., et al.
Publicado: (2013)

(131)I-metaiodobenzylguanidine ((131)I-MIBG) therapy for residual neuroblastoma: a mono-institutional experience with 43 patients
por: Garaventa, A, et al.
Publicado: (1999)

Designing and Comparing Performances of Image Processing Pipeline for Enhancement of I-131-metaiodobenzylguanidine Images
por: Pandey, Anil Kumar, et al.
Publicado: (2021)

The efficacy and safety of Iodine-131-metaiodobenzylguanidine therapy in patients with neuroblastoma: a meta-analysis
por: He, Huihui, et al.
Publicado: (2022)

I-131-Metaiodobenzylguanidine therapy with allogeneic cord blood stem cell transplantation for recurrent neuroblastoma
por: Sato, Yuya, et al.
Publicado: (2012)

Iodine-131 Metaiodobenzylguanidine Therapy for Neuroblastoma: Reports So Far and Future Perspective
por: Kayano, Daiki, et al.
Publicado: (2015)

Positive (68)Ga-DOTANOC PET/CT with negative (131)I- metaiodobenzylguanidine scan in a case of Glomus Jugulare
por: Damle, Nishikant A., et al.
Publicado: (2013)

The use of 131I-MIBG in the imaging of metastatic carcinoid tumours.
por: Jodrell, D. I., et al.
Publicado: (1988)

Targeted Radionuclide Therapy for Patients with Metastatic Pheochromocytoma and Paraganglioma: From Low-Specific-Activity to High-Specific-Activity Iodine-131 Metaiodobenzylguanidine
por: Jimenez, Camilo, et al.
Publicado: (2019)

Feasibility of High-dose Iodine-131-metaiodobenzylguanidine Therapy for High-risk Neuroblastoma Preceding Myeloablative Chemotherapy and Hematopoietic Stem Cell Transplantation: a Study Protocol
por: Araki, Raita, et al.
Publicado: (2018)

MON-202 Germline SDHB Exon 1 Deletion Is Associated with Absence of (131)I-metaiodobenzylguanidine (MIBG) Uptake in Malignant Paragangliomas
por: Petenuci, Janaina, et al.
Publicado: (2020)

Phase II study of pazopanib monotherapy in metastatic gastroenteropancreatic neuroendocrine tumours
por: Ahn, H K, et al.
Publicado: (2013)

Iodine-131MIBG SPECT/CT in neuroendocrine tumours: An institutional experience
por: Verma, Priyanka, et al.
Publicado: (2012)

Fractionated (131)I anti-CEA radioimmunotherapy: effects on xenograft tumour growth and haematological toxicity in mice
por: Violet, J A, et al.
Publicado: (2008)

(123)I‐Metaiodobenzylguanidine Myocardial Scintigraphy in Discriminating Degenerative Parkinsonisms
por: Catalan, Mauro, et al.
Publicado: (2021)

OR29-3 High-specific-activity Iodine 131 Metaiodobenzylguanidine for the Treatment of Advanced Pheochromocytoma and Paraganglioma: A Real-world Study
por: Al-ward, Ruaa
Publicado: (2022)

Phase I study of [(131)I] ICF01012, a targeted radionuclide therapy, in metastatic melanoma: MELRIV-1 protocol
por: Thivat, Emilie, et al.
Publicado: (2022)

Autonomic disorders and myocardial 123I-metaiodobenzylguanidine scintigraphy in Huntington’s disease
por: Assante, Roberta, et al.
Publicado: (2020)

EANM Dosimetry Committee series on standard operational procedures for internal dosimetry for (131)I mIBG treatment of neuroendocrine tumours
por: Gear, Jonathan, et al.
Publicado: (2020)

Two Cases of Decreased (123)I-Metaiodobenzylguanidine Lung Uptake in Metaiodobenzylguanidine Scintigraphy While Taking Selective Serotonin Reuptake Inhibitor/Serotonin Noradrenaline Reuptake Inhibitor
por: Adaniya, Shinobu, et al.
Publicado: (2021)

(123)I-Labelled metaiodobenzylguanidine for the evaluation of cardiac sympathetic denervation in early stage amyloidosis
por: Noordzij, Walter, et al.
Publicado: (2012)

Comparative evaluation of iodine-131 metaiodobenzylguanidine and 18-fluorodeoxyglucose positron emission tomography in assessing neural crest tumors: Will they play a complementary role?
por: Kundu, Soumyakanti, et al.
Publicado: (2017)

I -123 metaiodobenzylguanidine imaging for predicting ventricular arrhythmia in heart failure patients
por: Zhou, Weihua, et al.
Publicado: (2013)

Thyroid function after diagnostic (123)I-metaiodobenzylguanidine in children with neuroblastic tumors
por: Clement, Sarah C., et al.
Publicado: (2022)

Incorporation of high-dose (131)I-metaiodobenzylguanidine treatment into tandem high-dose chemotherapy and autologous stem cell transplantation for high-risk neuroblastoma: results of the SMC NB-2009 study
por: Lee, Ji Won, et al.
Publicado: (2017)

Sequelae and survivorship in patients treated with (131)I-MIBG therapy
por: Sze, W C C, et al.
Publicado: (2013)

Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours
por: Turner, N C, et al.
Publicado: (2010)

Outcomes of metastatic neuroendocrine carcinoma of the gallbladder
por: Ghosh, Joydeep, et al.
Publicado: (2021)

Phase I/II study of (131)I-MIBG with vincristine and 5 days of irinotecan for advanced neuroblastoma
por: DuBois, S G, et al.
Publicado: (2015)

Uptake Index of (123)I-metaiodobenzylguanidine Myocardial Scintigraphy for Diagnosing Lewy Body Disease
por: Kamiya, Yoshito, et al.
Publicado: (2017)

Cardiac 123I-Metaiodobenzylguanidine (MIBG) Scintigraphy in Parkinson’s Disease: A Comprehensive Review
por: Pitton Rissardo, Jamir, et al.
Publicado: (2023)

Treatment efficacy in a metastatic small intestinal neuroendocrine tumour grade 2 cohort
por: Papantoniou, Dimitrios, et al.
Publicado: (2023)

How I treat neuroendocrine tumours
por: Kiesewetter, Barbara, et al.
Publicado: (2020)

Thyroid Remnant Estimation by Diagnostic Dose (131) I Scintigraphy or (99m) T c O (4) (−) Scintigraphy after Thyroidectomy: A Comparison with Therapeutic Dose (131) I Imaging
por: Liu, Guanghui, et al.
Publicado: (2016)

Destabilization of MYC/MYCN by the mitochondrial inhibitors, metaiodobenzylguanidine, metformin and phenformin
por: WANG, STEPHANIE S., et al.
Publicado: (2014)

Cardiac (123)I-metaiodobenzylguanidine Scintigraphy in a Patient with Familial Parkinsonism with Parkin Gene Mutation
por: Kim, Young-Do, et al.
Publicado: (2010)

(123)I-Metaiodobenzylguanidine Myocardial Scintigraphy in Lewy Body-Related Disorders: A Literature Review
por: Chung, Eun Joo, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_q7679hdqim9kdl5e21or96q3ur